Detecting and identifying antibiotic resistance genes in bloodstream infections
Official title: Direct detection and identification of antimicrobial resistance genes in bloodstream infections
Funded at Helixbind, INC. · NIH-10898697 · Data updated 2026-11-12
This study is testing a new, faster way to diagnose bloodstream infections using a special tool called RaPID, which can give results in about three hours directly from patient samples, making it especially helpful for those who have already started treatment.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Helixbind, INC. NIH-funded |
| Lab location | 1 site (Boxborough, UNITED STATES) |
| Project start | August 9, 2022 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R44AI172441-03 |
| Project ID | NIH-10898697 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients suspected of having bloodstream infections, particularly those who may have received prior antimicrobial treatment.
✕Less likely to help
Patients with infections that are not bloodstream-related or those who do not have any signs of infection may not benefit from this research.
What this research studies
This research focuses on improving the diagnosis of bloodstream infections (BSIs) by developing a new diagnostic platform called RaPID, which can quickly identify and characterize infections directly from patient samples without the need for traditional blood cultures. The RaPID system operates using single-use cassettes and provides results in approximately three hours, significantly faster than current methods that can take 1-3 days. This innovative approach aims to enhance the accuracy of diagnosing infections, especially in cases where patients have already received antimicrobial treatment, which can complicate traditional testing methods.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate diagnoses of bloodstream infections, ultimately improving patient outcomes and reducing hospital stays.
How similar studies have gone: Other research has shown success with similar rapid diagnostic approaches, indicating a promising potential for this novel method.
Where this research is happening
-
Helixbind, INC.
Boxborough, United States Active
Researchers
- Principal investigator: Singer, Alon — Helixbind, INC.
- Study coordinator: Singer, Alon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.